PSivida: Durasert Second Phase 3 Trial Meets Primary Efficacy Goal

More notable recent pSivida Corp. (NASDAQ:PSDV) will announce $550,000.00 in sales for the current quarter, according to Zacks.

The number of shares now held by investors is 39.36 Million. The original version of this piece can be viewed at Geode Capital Management LLC boosted its stake in shares of pSivida 0.5% in the first quarter. Geode Capital Management LLC now owns 143,049 shares of the company's stock valued at $246,000 after buying an additional 756 shares in the last quarter. Renaissance Technologies LLC increased its stake in pSivida 34.0% in the fourth quarter.

Durasert three-year insert demonstrated a significant reduction in the recurrence of posterior segment uveitis through six months, the company said. Vanguard Group Inc. increased its position in shares of pSivida 3.5% in the first quarter. The company generates revenue of $1.43 Billion and has a net income of $-140.80 Million, for the trailing twelve months. (NASDAQ:PSDV) news were published by: which released: "BRIEF-Pfizer reports 4.7 pct stake in pSivida Corp as of May 15 - SEC filing" on May 26, 2017, also with their article: "An Eye On Ophthalmology: Analyzing pSivida's Upcoming Clinical Trial" published on May 17, 2017, published: "pSivida Corp". Insiders own 2.59% of the company's stock.

pSivida Corp. (NASDAQ:PSDV) on Tuesday closed at $1.75. The firm has a 50-day moving average of $1.79 and a 200 day moving average of $1.80.

Currently, the market capitalization of pSivida Corp. Equities research analysts expect that pSivida Corp. will post ($0.51) EPS for the current fiscal year. Virginia-based Thompson Siegel & Walmsley Limited Liability Corporation has invested 0% in pSivida Corp. (NASDAQ:PSDV) for 205,400 shares. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & global copyright & trademark law. For the current quarter Psivida Corp Com (NASDAQ:PSDV) has high EPS estimates of $-0.12 in contradiction of low EPS estimates of $-0.17. Several analysts have commented on the company. HC Wainwright set a $8.00 target price on pSivida Corp. and gave the stock a "buy" rating in a research report on Wednesday. Therefore 100% are positive. pSivida had 3 analyst reports since October 15, 2015 according to SRatingsIntel.

02/21/2014 - pSivida Corp. was upgraded to "hold" by analysts at Jefferson Research. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. The lowest target is $6.0 while the high is $8. Given that liquidity is king in short-term, VALE is a stock with 5.01 billion shares outstanding that normally trades 2.88% of its float. A total of 6.04 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 486.33 Million shares, while its relative volume stands at 12.43. EPS breaks down the profitability of the company on a single share basis.

Watertown, MA-based pSivida says their lead eye drug for posterior segment uveitis hit the primary endpoint of their second Phase III trial, putting them on track to a European filing this month with an FDA application scheduled to arrive in Q4.

  • Zachary Reyes